Published in Hepatology on November 01, 2008
CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol (2011) 3.73
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
CXCR3 in T cell function. Exp Cell Res (2011) 2.54
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest (2010) 2.43
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology (2015) 1.68
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One (2015) 1.49
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol (2008) 1.26
CXCR2-dependent mucosal neutrophil influx protects against colitis-associated diarrhea caused by an attaching/effacing lesion-forming bacterial pathogen. J Immunol (2009) 1.24
Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol (2011) 1.18
Mononuclear cells in liver fibrosis. Semin Immunopathol (2009) 1.15
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis (2011) 1.12
Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol (2011) 1.06
CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J Autoimmun (2010) 1.03
Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc Natl Acad Sci U S A (2012) 1.01
Telaprevir-based treatment effects on hepatitis C virus in liver and blood. Hepatology (2014) 0.99
The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics (2014) 0.99
Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection. J Virol (2013) 0.98
Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes. J Hepatol (2013) 0.96
Expression profiles of circulating cytokines, chemokines and immune cells in patients with hepatitis B virus infection. Hepat Mon (2014) 0.93
Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin Immunopathol (2009) 0.91
The role of CXCR3 in the induction of primary biliary cirrhosis. Clin Dev Immunol (2011) 0.89
The role of chemokines in acute and chronic hepatitis C infection. Cell Mol Immunol (2013) 0.89
Clinical implications of chemokines in acute and chronic hepatitis C virus infection. Yonsei Med J (2011) 0.89
Dipyrithione inhibits IFN-gamma-induced JAK/STAT1 signaling pathway activation and IP-10/CXCL10 expression in RAW264.7 cells. Inflamm Res (2010) 0.88
Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J Infect Dis (2014) 0.87
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J (2011) 0.85
The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C. PLoS One (2012) 0.85
The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol (2013) 0.84
Chemokine antagonism in chronic hepatitis C virus infection. J Clin Invest (2010) 0.83
Molecular targets in the treatment of alcoholic hepatitis. World J Gastroenterol (2012) 0.82
CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep (2016) 0.81
The role of chemokines in hepatitis C virus-mediated liver disease. Int J Mol Sci (2014) 0.81
CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating, through an interaction with Toll-like receptor 2 and hyaluronan. J Virol (2012) 0.81
Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis (2010) 0.80
Chemokine Transfer by Liver Sinusoidal Endothelial Cells Contributes to the Recruitment of CD4+ T Cells into the Murine Liver. PLoS One (2015) 0.79
A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer (2015) 0.79
Hepatic serum amyloid A1 aggravates T cell-mediated hepatitis by inducing chemokines via Toll-like receptor 2 in mice. J Biol Chem (2015) 0.79
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. J Transl Med (2012) 0.78
Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis. Expert Rev Clin Immunol (2016) 0.78
The role of interferon-γ inducible protein-10 in a mouse model of acute liver injury post induced pluripotent stem cells transplantation. PLoS One (2012) 0.78
Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. Clin Rheumatol (2013) 0.78
Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection. HIV Med (2016) 0.78
IP-10 can be measured in dried plasma spots in patients with chronic hepatitis C infection. PLoS One (2012) 0.77
Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B. World J Gastroenterol (2010) 0.77
HIV-1 coinfection profoundly alters intrahepatic chemokine but not inflammatory cytokine profiles in HCV-infected subjects. PLoS One (2014) 0.77
Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin. J Infect Dis (2014) 0.76
Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother (2011) 0.76
Comparative Analysis of Liver Injury-Associated Cytokines in Acute Hepatitis A and B. Yonsei Med J (2016) 0.76
Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas. World J Gastroenterol (2015) 0.76
Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients. Aliment Pharmacol Ther (2015) 0.76
Identifying molecular targets to improve immune function in alcoholic hepatitis. Gastroenterology (2015) 0.76
Effects of the Chemokine Receptor 5 (CCR5)-Delta32 Mutation on Hepatitis C Virus-Specific Immune Responses and Liver Tissue Pathology in HCV Infected Patients. Hepat Mon (2014) 0.75
Emerging new chemokine CXCR3 antagonists and their potential clinical and therapeutic applications. Hepatology (2009) 0.75
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. Liver Int (2015) 0.75
In vivo Ebola virus infection leads to a strong innate response in circulating immune cells. BMC Genomics (2016) 0.75
Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. Virol J (2016) 0.75
B-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-γ-Inducible Protein-10 in Autoimmune Hepatitis. Medicine (Baltimore) (2016) 0.75
Editorial Commentary: Another Call to Cure Hepatitis B. Clin Infect Dis (2015) 0.75
Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China. Gut Liver (2016) 0.75
Predictive Value of Serum IFN-γ inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients. Sci Rep (2017) 0.75
Liver inflammation in a mouse model of Th1 hepatitis despite the absence of invariant NKT cells or the Th1 chemokine receptors CXCR3 and CCR5. Lab Invest (2012) 0.75
CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study. Clin Transl Med (2017) 0.75
CXCL10 is produced in hepatitis A virus-infected cells in an IRF3-dependent but IFN-independent manner. Sci Rep (2017) 0.75
Chemokine receptor CXCR3 in turbot (Scophthalmus maximus): cloning, characterization and its responses to lipopolysaccharide. Fish Physiol Biochem (2015) 0.75
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
The biology of chemokines and their receptors. Annu Rev Immunol (2000) 9.81
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 8.56
International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 7.17
The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest (1998) 6.51
Classification of chronic viral hepatitis: a need for reassessment. J Hepatol (1991) 5.23
DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol (2001) 4.22
Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology (1999) 3.73
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat (2007) 2.19
The long-term pathological evolution of chronic hepatitis C. Hepatology (1996) 2.15
Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol (2003) 2.13
The natural history of hepatitis C. Semin Liver Dis (2004) 1.95
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol (2002) 1.62
Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology (2005) 1.52
Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology (2004) 1.50
Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver (2002) 1.24
Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol (2001) 1.08
Hepatic inflammation and immunity: a summary of a conference on the function of the immune system within the liver. Hepatology (2000) 0.92
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J Am Med Inform Assoc (2009) 3.62
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Automated acquisition of disease drug knowledge from biomedical and clinical documents: an initial study. J Am Med Inform Assoc (2007) 3.09
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Mining a clinical data warehouse to discover disease-finding associations using co-occurrence statistics. AMIA Annu Symp Proc (2005) 2.75
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun (2005) 2.52
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells. J Hepatol (2003) 2.31
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Gene symbol disambiguation using knowledge-based profiles. Bioinformatics (2007) 2.13
Inter-patient distance metrics using SNOMED CT defining relationships. J Biomed Inform (2006) 2.12
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Machine learning and word sense disambiguation in the biomedical domain: design and evaluation issues. BMC Bioinformatics (2006) 1.93
Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation (2012) 1.93
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 1.77
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology (2006) 1.69
Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res (2005) 1.68
Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol (2008) 1.65
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol (2008) 1.61
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry (2005) 1.58
c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in mice. J Biol Chem (2011) 1.57
Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl (2003) 1.57
Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol (2008) 1.48
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
Combining knowledge and data driven insights for identifying risk factors using electronic health records. AMIA Annu Symp Proc (2012) 1.46
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46
HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levels. J Acquir Immune Defic Syndr (2006) 1.44
A statistical methodology for analyzing co-occurrence data from a large sample. J Biomed Inform (2006) 1.43
Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med (2008) 1.42
Imaging appearance in acute liver failure: correlation with clinical and pathology findings. Dig Dis Sci (2014) 1.39
Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol (2008) 1.39
Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest (2009) 1.38
Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant (2007) 1.37
Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection. J Am Med Inform Assoc (2011) 1.36
Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis (2009) 1.36
Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood (2003) 1.33
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis (2005) 1.31
Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2007) 1.30
Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol (2006) 1.29
Ecto-5'-nucleotidase (CD73) -mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J (2008) 1.28
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol (2008) 1.24
Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2008) 1.23
Liver-specific loss of glucose-regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice. Hepatology (2011) 1.23
Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol (2007) 1.22
Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest (2005) 1.22
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol (2010) 1.22
Role of fine-needle aspiration cytology in breast lymphoma. Diagn Cytopathol (2004) 1.21
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis (2012) 1.20
Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol (2003) 1.19
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One (2012) 1.19
Subdiaphragmatic bronchogenic cysts: a comprehensive review of the literature. Am Surg (2005) 1.19
Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant (2003) 1.18
Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis (2003) 1.18
Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin? Mod Pathol (2007) 1.18
Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol (2011) 1.18
Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology (2008) 1.16